@article{Davis2021c,
abstract = {A dysregulated host immune response significantly contributes to morbidity and mortality in tuberculous meningitis (TBM). Effective host directed therapies (HDTs) are critical to improve survival and clinical outcomes. Currently only one HDT, dexamethasone, is proven to improve mortality. However, there is no evidence dexamethasone reduces morbidity, how it reduces mortality is uncertain, and it has no proven benefit in HIV co-infected individuals. Further research on these aspects of its use, as well as alternative HDTs such as aspirin, thalidomide and other immunomodulatory drugs is needed. Based on new knowledge from pathogenesis studies, repurposed therapeutics which act upon small molecule drug targets may also have a role in TBM. Here we review existing literature investigating HDTs in TBM, and propose new rationale for the use of novel and repurposed drugs. We also discuss host variable responses and evidence to support a personalised approach to HDTs in TBM.},
author = {Davis, Angharad G and Donovan, Joseph and Bremer, Marise and {Van Toorn}, Ronald and Schoeman, Johan and Dadabhoy, Ariba and Lai, Rachel P J and Cresswell, Fiona V and Boulware, David R and Wilkinson, Robert J and Thuong, Nguyen Thuy Thuong and Thwaites, Guy E and Bahr, Nathan C and {Tuberculous Meningitis International Research Consortium}},
doi = {10.12688/wellcomeopenres.16474.2},
file = {:C$\backslash$:/Users/01462563/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/Davis et al. - 2021 - Host directed therapies for tuberculous meningitis version 2 peer review 2 approved.pdf:pdf},
journal = {Wellcome Open Research},
keywords = {Dexamethasone,Host Directed Therapies,OA,Tuberculous Meningitis,fund{\_}ack,review},
mendeley-tags = {OA,fund{\_}ack,review},
month = {jul},
pages = {292},
pmid = {35118196},
publisher = {F1000 Research Limited},
title = {{Host directed therapies for tuberculous meningitis [version 2; peer review: 2 approved]}},
url = {https://wellcomeopenresearch.org/articles/5-292},
volume = {5},
year = {2021}
}

{"_id":"rhSXiPzkHSSvhSzQD","bibbaseid":"davis-donovan-bremer-vantoorn-schoeman-dadabhoy-lai-cresswell-etal-hostdirectedtherapiesfortuberculousmeningitisversion2peerreview2approved-2021","author_short":["Davis, A. G","Donovan, J.","Bremer, M.","Van Toorn, R.","Schoeman, J.","Dadabhoy, A.","Lai, R. P J","Cresswell, F. V","Boulware, D. R","Wilkinson, R. J","Thuong, N. T. T.","Thwaites, G. E","Bahr, N. C","Tuberculous Meningitis International Research Consortium"],"bibdata":{"bibtype":"article","type":"article","abstract":"A dysregulated host immune response significantly contributes to morbidity and mortality in tuberculous meningitis (TBM). Effective host directed therapies (HDTs) are critical to improve survival and clinical outcomes. Currently only one HDT, dexamethasone, is proven to improve mortality. However, there is no evidence dexamethasone reduces morbidity, how it reduces mortality is uncertain, and it has no proven benefit in HIV co-infected individuals. Further research on these aspects of its use, as well as alternative HDTs such as aspirin, thalidomide and other immunomodulatory drugs is needed. Based on new knowledge from pathogenesis studies, repurposed therapeutics which act upon small molecule drug targets may also have a role in TBM. Here we review existing literature investigating HDTs in TBM, and propose new rationale for the use of novel and repurposed drugs. We also discuss host variable responses and evidence to support a personalised approach to HDTs in TBM.","author":[{"propositions":[],"lastnames":["Davis"],"firstnames":["Angharad","G"],"suffixes":[]},{"propositions":[],"lastnames":["Donovan"],"firstnames":["Joseph"],"suffixes":[]},{"propositions":[],"lastnames":["Bremer"],"firstnames":["Marise"],"suffixes":[]},{"propositions":[],"lastnames":["Van Toorn"],"firstnames":["Ronald"],"suffixes":[]},{"propositions":[],"lastnames":["Schoeman"],"firstnames":["Johan"],"suffixes":[]},{"propositions":[],"lastnames":["Dadabhoy"],"firstnames":["Ariba"],"suffixes":[]},{"propositions":[],"lastnames":["Lai"],"firstnames":["Rachel","P","J"],"suffixes":[]},{"propositions":[],"lastnames":["Cresswell"],"firstnames":["Fiona","V"],"suffixes":[]},{"propositions":[],"lastnames":["Boulware"],"firstnames":["David","R"],"suffixes":[]},{"propositions":[],"lastnames":["Wilkinson"],"firstnames":["Robert","J"],"suffixes":[]},{"propositions":[],"lastnames":["Thuong"],"firstnames":["Nguyen","Thuy","Thuong"],"suffixes":[]},{"propositions":[],"lastnames":["Thwaites"],"firstnames":["Guy","E"],"suffixes":[]},{"propositions":[],"lastnames":["Bahr"],"firstnames":["Nathan","C"],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["Tuberculous Meningitis International Research Consortium"],"suffixes":[]}],"doi":"10.12688/wellcomeopenres.16474.2","file":":C$\\$:/Users/01462563/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/Davis et al. - 2021 - Host directed therapies for tuberculous meningitis version 2 peer review 2 approved.pdf:pdf","journal":"Wellcome Open Research","keywords":"Dexamethasone,Host Directed Therapies,OA,Tuberculous Meningitis,fund_ack,review","mendeley-tags":"OA,fund_ack,review","month":"jul","pages":"292","pmid":"35118196","publisher":"F1000 Research Limited","title":"Host directed therapies for tuberculous meningitis [version 2; peer review: 2 approved]","url":"https://wellcomeopenresearch.org/articles/5-292","volume":"5","year":"2021","bibtex":"@article{Davis2021c,\r\nabstract = {A dysregulated host immune response significantly contributes to morbidity and mortality in tuberculous meningitis (TBM). Effective host directed therapies (HDTs) are critical to improve survival and clinical outcomes. Currently only one HDT, dexamethasone, is proven to improve mortality. However, there is no evidence dexamethasone reduces morbidity, how it reduces mortality is uncertain, and it has no proven benefit in HIV co-infected individuals. Further research on these aspects of its use, as well as alternative HDTs such as aspirin, thalidomide and other immunomodulatory drugs is needed. Based on new knowledge from pathogenesis studies, repurposed therapeutics which act upon small molecule drug targets may also have a role in TBM. Here we review existing literature investigating HDTs in TBM, and propose new rationale for the use of novel and repurposed drugs. We also discuss host variable responses and evidence to support a personalised approach to HDTs in TBM.},\r\nauthor = {Davis, Angharad G and Donovan, Joseph and Bremer, Marise and {Van Toorn}, Ronald and Schoeman, Johan and Dadabhoy, Ariba and Lai, Rachel P J and Cresswell, Fiona V and Boulware, David R and Wilkinson, Robert J and Thuong, Nguyen Thuy Thuong and Thwaites, Guy E and Bahr, Nathan C and {Tuberculous Meningitis International Research Consortium}},\r\ndoi = {10.12688/wellcomeopenres.16474.2},\r\nfile = {:C$\\backslash$:/Users/01462563/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/Davis et al. - 2021 - Host directed therapies for tuberculous meningitis version 2 peer review 2 approved.pdf:pdf},\r\njournal = {Wellcome Open Research},\r\nkeywords = {Dexamethasone,Host Directed Therapies,OA,Tuberculous Meningitis,fund{\\_}ack,review},\r\nmendeley-tags = {OA,fund{\\_}ack,review},\r\nmonth = {jul},\r\npages = {292},\r\npmid = {35118196},\r\npublisher = {F1000 Research Limited},\r\ntitle = {{Host directed therapies for tuberculous meningitis [version 2; peer review: 2 approved]}},\r\nurl = {https://wellcomeopenresearch.org/articles/5-292},\r\nvolume = {5},\r\nyear = {2021}\r\n}\r\n","author_short":["Davis, A. G","Donovan, J.","Bremer, M.","Van Toorn, R.","Schoeman, J.","Dadabhoy, A.","Lai, R. P J","Cresswell, F. V","Boulware, D. R","Wilkinson, R. J","Thuong, N. T. T.","Thwaites, G. E","Bahr, N. C","Tuberculous Meningitis International Research Consortium"],"key":"Davis2021c","id":"Davis2021c","bibbaseid":"davis-donovan-bremer-vantoorn-schoeman-dadabhoy-lai-cresswell-etal-hostdirectedtherapiesfortuberculousmeningitisversion2peerreview2approved-2021","role":"author","urls":{"Paper":"https://wellcomeopenresearch.org/articles/5-292"},"keyword":["Dexamethasone","Host Directed Therapies","OA","Tuberculous Meningitis","fund_ack","review"],"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"https://drive.google.com/uc?export=download&id=1-JLqZ7RwZ3VC2d6ErLGHAtOeMRS_7GCz","dataSources":["Krmt6gt9ktB2s6ARh"],"keywords":["dexamethasone","host directed therapies","oa","tuberculous meningitis","fund_ack","review"],"search_terms":["host","directed","therapies","tuberculous","meningitis","version","peer","review","approved","davis","donovan","bremer","van toorn","schoeman","dadabhoy","lai","cresswell","boulware","wilkinson","thuong","thwaites","bahr","tuberculous meningitis international research consortium"],"title":"Host directed therapies for tuberculous meningitis [version 2; peer review: 2 approved]","year":2021}